Filing Details

Accession Number:
0001298711-22-000007
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-11-10 17:05:29
Reporting Period:
2022-11-08
Accepted Time:
2022-11-10 17:05:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1711279 Krystal Biotech Inc. KRYS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1298711 Suma Krishnan C/O Krystal Biotech, Inc.
2100 Wharton Street, Suite 701
Pittsburgh PA 15203
President, R&D Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-11-08 823 $80.04 1,726,440 No 4 S Direct
Common Stock Disposition 2022-11-08 966 $80.05 1,787,722 No 4 S Indirect By Spouse
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Indirect By Spouse
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 90,000 Indirect By SMK Trust
Common Stock 50,000 Indirect By Krishan Family Trust
Footnotes
  1. The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share.
  2. The transaction was executed in multiple trades ranging from $80.0000 to $80.1900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  3. The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share.
  4. These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan.
  5. Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.
  6. Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.